STOCK TITAN
  1. Home
  2. News
  3. CSTL

Castle Biosciences - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (CSTL) delivers innovative diagnostic solutions that transform cancer care through genomic insights. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in precision oncology diagnostics.

Access authoritative information about CSTL’s latest developments, including new test validations, clinical study results, and strategic partnerships. Our curated collection features earnings reports, regulatory milestones, and research breakthroughs across key focus areas like melanoma diagnostics and pharmacogenomics.

Stay informed about critical updates including:
- FDA-cleared test announcements
- Peer-reviewed study publications
- Financial performance reports
- Collaborative oncology initiatives
- Expanded clinical utility data

Bookmark this page for streamlined access to Castle Biosciences’ verified news. Check regularly for updates that impact diagnostic practices and investment considerations in the genomic testing sector.

News

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) receives the Top Workplaces USA award for the third year in a row, ranking 28th among 370 companies. The company is recognized for its exceptional workplace culture that prioritizes employee empowerment, trust, transparency, and authenticity. The award is attributed to the dedication of Castle's employees and their commitment to improving health through innovative tests that guide patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
News

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Rhea-AI Summary
Castle Biosciences presents new data at SSO 2024 demonstrating DecisionDx-Melanoma's ability to predict risk of sentinel lymph node positivity in patients with cutaneous melanoma. The test can help identify high-risk patients who may benefit from more intensive treatment pathways, such as sentinel lymph node biopsy and imaging surveillance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
News

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) releases expert consensus guidelines on the use of DecisionDx-SCC test in determining adjuvant radiation therapy for high-risk squamous cell carcinoma patients. The guidelines aim to improve precision in treatment recommendations based on risk assessment and AJCC8 staging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
News

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces new data highlighting the value of its IDgenetix pharmacogenomic (PGx) test in guiding medication recommendations for older adults with mental health conditions. The study shows one-third of medication recommendations were due to drug-drug interactions and lifestyle factors, emphasizing the importance of personalized medication selection in elderly patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
News

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on March 19, 2024. The live webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences
-
News

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces data presentations at AAD Annual Meeting showcasing improved survival in patients with cutaneous melanoma using DecisionDx-Melanoma test. The company's gene expression profile tests demonstrate effectiveness in guiding personalized care for skin cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
conferences
News

In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces the largest study of its DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma, demonstrating improved predictive accuracy and personalized treatment pathways. The study highlights the test's ability to guide risk-appropriate treatment decisions, reducing overtreatment and undertreatment, based on patients' biological risk of metastasis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
none
-
News

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Rhea-AI Summary
Castle Biosciences (CSTL) reports a strong performance in 2023, with $220 million revenue, a 60% increase from 2022, and 70,429 test reports delivered. The company also achieved $243 million in cash, two critical publications associating with DecisionDx-Melanoma testing, and a successful conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.95%
Tags
earnings
-
News

Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announced study results demonstrating the superior risk stratification of DecisionDx-Melanoma in stage I melanoma patients. The study, including 5,651 patients, showed better outcomes than AJCC8 staging. Incorporating DecisionDx-Melanoma may enhance clinical decision-making for more precise information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
News

Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. The company will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Access details for the webcast and phone conference call are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
Stock CSTL logo
Castle Biosciences

Nasdaq:CSTL

CSTL Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CSTL Stock Data

620.45M
28.04M
3.35%
93.97%
6.48%
Diagnostics & Research
Services-medical Laboratories
Link
United States
FRIENDSWOOD